Journal of Cancer Biology and Clinical Oncology


Targeting Cyclin E by Phellinus Linteus for Colon Cancer Therapeutics

Author(s): Suthakar Ganapathy, Tianqi Yu, Ling Shen, Bo Peng, Sung-Hoon Kim and Changyan Chen

Purpose: Colon cancer is a common malignant disease with a high rate of cancer-related deaths. Current conventional chemotherapies to treat advanced colon cancer are not effective and often have serious side effects. Thus, there is an urgent need for discovering new treatments with a high efficacy and less toxicity. Because phellinus linteus (PL) has been widely used in Asia to treat cancers, we in this study investigated how the polysaccharides (P-PL) extracted from PL effectively targeted colon cancer cells. Methods: P-PL was used to test its effects on Human colon epithelial-like Caco-2 and cancerous HCT116 or HT29 cells IN VITRO and IN VIVO. The assays to analyze cell cycle progression, the expressions of G1/S cyclins and function of mRNA binding protein HuR were conducted for investigating the molecular mechanisms of the anti-colon cancer action of P-PL. 
Results: In this study, we demonstrated that P-PL treatment preferentially induced human colon cancer HCT116 or HT29 cells to apoptosis, but had a little cytotoxicity to the control, immortalized colon epithelial-like Caco-2 cells. P-PL-treated colon cancer cells accumulate in S phase of the cell cycle before underwent apoptosis. In this process, cyclin E (clnE) expression is decreased, which is due to the decrease of its mRNA stability. Furthermore, HuR function in treated cancer cells is perturbed. 
Conclusion: Taken together, our findings strongly suggest that P-PL is a potential anti-cancer medicine that can block malignant growth of colon cancer and has less cytotoxic side effects.

Mission and Vision Membership Withdrawal Policy Submit Paper Publication ethics
Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License © 2018